C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home › Markets › Loading…
FORA Equity

FORA

OTCMKTS · FORA

$2.66
—
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 2/5
45/100 composite
Fundamentals52
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

CIN assigns Forian a Neutral rating in the Neutral band, with a mid-40s composite and low conviction. Fundamentals provide the largest contribution, scoring in the low 50s, supported primarily by a gross-margin subscore near 80 and a cash-runway subscore above 60. Regulatory ranks second at just under 50, as a neutral jurisdiction posture and a strong enforcement subscore offset weak filing cadence. Market contribution sits near 40 because no institutional quote is available, while editorial contribution trails near 30 due to absent newsroom and brief activity. The pillar mix supports neither a premium stance nor a decisive negative call.

Licensed fundamentals data show revenue contracting by roughly 3% year over year. Gross margin remains close to 47%, representing the clearest operating strength, but the operating loss exceeds half of revenue and prevents that margin from producing viable earnings. EBITDA remains negative at approximately $5.6 million, while the bottom-line loss stands near $5.1 million. The cash-burn ratio is a little above 8%, and the stated financial condition remains stretched. Primary regulatory filings show no recorded filing date and no identified regulatory events across either the latest 90-day or 180-day periods. The cadence subscore near 25 constrains regulatory confidence despite no enforcement hits and an enforcement subscore around 80. Institutional pricing feeds provide no current quote, while CIN newsroom coverage contains no recent newsroom or brief hits.

The forward catalyst rests squarely on fundamentals, the strongest pillar. Forian’s gross-margin profile demonstrates underlying economic value, but a re-rating requires evidence that this margin base can translate into lower operating losses and renewed top-line expansion. Stable gross margin near the high-40% area, paired with tighter cost absorption, would lift the weakest components within the fundamentals pillar and strengthen the composite from its current Neutral position. More consistent primary regulatory filings would improve transparency, although filing cadence remains secondary to operating execution. The single most important signal to watch is sustained operating-margin improvement generated from the existing gross-margin base.

Scored: 2026-10-14Valid through: 2026-11-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
Corporate DetailsCompany profile
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$67.8M
Enterprise value
$36.3M
PEG ratio
0.94
Price to book
2.28
Price to sales
2.26
EV / EBITDA
20.05
Revenue (TTM)
$30.1M
Gross profit (TTM)
$14.2M
EBITDA
$-5.6M
Operating margin
-50.9%
Profit margin
-17.0%
Rev growth YoY
-2.9%
Return on equity
-17.9%
Return on assets
-8.4%
EPS (TTM)
$-0.09
EPS est. current year
$0.09
Wall St. target price
$2.10
Shares outstanding
31.2M
Insider ownership
51.8%
Institutional ownership
14.9%
Beta
0.93
Full-time employees
50
GICS sector
Healthcare
GICS industry
Health Information Services
Filings & DisclosuresPrimary sources
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for FORA (FORA)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for FORA (FORA), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for FORA are maintained by Cannabis Investor News and refreshed throughout the trading day.